Quality of Life Assessment with the Medical Outcomes Study Short Form-36 among Patients with Cervical Spondylotic Myelopathy

King, Joseph T.; McGinnis, Kathleen A.; Roberts, Mark S.

doi:10.1227/00006123-200301000-00014

Cited by 18 publications

(21 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequency of manifestation of the symptoms corresponds with the frequency described by other authors [6,12,15,17], the data also confirms that funicular and radicular symptoms are usually combined in CSM [9,10,18]. Postoperatively 51.9% of the patients showed improvement of the clinical symptoms.…”

Section: Clinical Datasupporting

confidence: 88%

Analysis of five specific scores for cervical spondylogenic myelopathy

2007

View full text Add to dashboard Cite

The ability to compare various results that measure clinical deficits and outcome is a necessity for successful worldwide discussion about cervical spondylogenic myelopathy (CSM) and its treatment. There is hardly any information in literature how to value and compare outcome assessed by different scores. In a retrospective study we objectively evaluated the Nurick-score, Japanese-orthopaedic-association-score (JOA-Score), Cooper-myelopathyscale (CMS), Prolo-score and European-myelopathy-score (EMS) using the data of 43 patients, all of whom showed clinical and morphological signs of CSM and underwent operative decompression. The scores were assessed pre-and postoperatively. The correlation between the scoreresults, anamnesis, clinical and diagnostic data was investigated. All the scores show a statistically significant correlation and measure postoperative improvement. With exception of the Prolo-score all scores reflect clinical deficits of CSM. The Prolo-score rates the severity of CSM on the state of the economic situation above clinical symptoms. The main differences of the scores are shown in the number of patients showing postoperative improvement, varying between 33% (Nurick-score) and 81% (JOA-score). The recovery-rates, as a measure of the cumulative improvement of all the symptoms, show less variation (23-37%). The differences of the recovery-rate were only statistically significant between JOA-score, Nurick-score and EMS (P \ 0.05), whereas all the other scores showed no significant differences. To assess the postoperative successes, the evaluation of the recovery-rate is essential. There is no significant difference in the recovery-rate amongst the majority of the scores, which allows a good comparison of the results from different studies. Nevertheless, it is always important to differentiate the therapy results of CSM published worldwide.

show abstract

Section: Clinical Datasupporting

confidence: 88%

Analysis of five specific scores for cervical spondylogenic myelopathy

2007

View full text Add to dashboard Cite

show abstract

“…QoL was assessed with the Medical Outcomes Study Short Form-36 [18]. This questionnaire comprises 36 items measuring patient's response in eight health domains (physical functioning, physical role functioning, bodily pain, general health, vitality, social functioning, emotional role functioning, and mental health), summarized in PCS (physical component summary) and MCS (mental component summary).…”

Section: Assessment Of the Quality Of Lifementioning

confidence: 99%

Comparison of Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy of Acoustic Neurinomas According to 3-D Tumor Volume Shrinkage and Quality of Life

et al. 2009

View full text Add to dashboard Cite

show abstract

“…They provided Class II-III evidence in support of the MDI, JOA, and SF-36 scales as valid and reliable tools for assessing patients undergoing surgery for CSM. This evidence was based on 4 studies: 1) the aforementioned study by Singh and Crockard, 22 2) a study by Yonenobu et al 30 (n = 29; 1-to 6-week follow-up) evaluating the JOA scale for CSM that found high inter-and intraobserver reliability of the scale, 3) a study by King et al 12 (n = 88; 1-year follow-up) evaluating the SF-36 scale for CSM that found high validity of the SF-36 when compared with the Nurick and JOA scales, and 4) a study by Singh et al 23 (n = 105, 6-month follow-up) that found high validity for both the SF-12 and SF-36.…”

Section: Discussionmentioning

confidence: 99%

Correlation of quality of life and functional outcome measures for cervical spondylotic myelopathy

Lubelski

Alvin

Nesterenko

et al. 2016

SPI

View full text Add to dashboard Cite

OBJECT Studies comparing surgical treatments for cervical spondylotic myelopathy (CSM) are heterogeneous, using a variety of different quality of life (QOL) outcomes and myelopathy-specific measures. This study sought to evaluate the relationship of these measures to each other, and to better understand their use in evaluating patients with CSM. METHODS A retrospective study was performed in all patients with CSM who underwent either ventral or dorsal cervical spine surgery at a single tertiary-care institution between January 2008 and July 2013. Severity of myelopathy was assessed pre- and postoperatively using both the Nurick scale and the modified Japanese Orthopaedic Association (mJOA) classification of disability. Prospectively collected QOL outcomes data included Pain Disability Questionnaire (PDQ), Patient Health Questionnaire–9 (PHQ-9), and EQ-5D. Spearman rank correlations were calculated to assess the construct convergent validity for each pair of health status measures (HSMs). To assess each HSM’s ability to discriminate favorable EQ-5D index, we performed receiver operating characteristic (ROC) curve analysis and assessed the area under the curve (AUC). RESULTS A total of 119 patients were included. The PDQ total score had the highest correlation with EQ-5D index (Spearman’s rho = −0.82). Neither of the myelopathy scales (mJOA or Nurick) had strong correlations between themselves (0.41) or with the other QOL measures (absolute value range 0.13–0.49). In contrast, the QOL measures correlated relatively well with each other (absolute value range 0.68–0.97). For predicting favorable EQ-5D outcomes, PDQ total score had an AUC of 0.909. The AUCs were significantly greater for the QOL measures in comparison with the myelopathy measures (AUCs were 0.677 and 0.607 for mJOA and Nurick scale scores, respectively). CONCLUSIONS The authors found that all included measures of QOL and CSM-specific (mJOA or Nurick scale) measures were valid and responsive. The PDQ was the most predictive of positive QOL after surgery (as measured by the EQ-5D index) for patients with CSM. The substantially lower correlation between myelopathy and QOL outcomes, compared with the various QOL measures themselves, suggests that these questionnaires are measuring different aspects of the patient experience. Solely assessing the myelopathy or disease-specific signs and symptoms is likely insufficient to fully understand and appreciate clinical outcome in its totality. These questionnaire types should be used together to best evaluate patients pre- and postoperatively.

show abstract

Quality of Life Assessment with the Medical Outcomes Study Short Form-36 among Patients with Cervical Spondylotic Myelopathy

Cited by 18 publications

References 25 publications

Analysis of five specific scores for cervical spondylogenic myelopathy

Analysis of five specific scores for cervical spondylogenic myelopathy

Comparison of Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy of Acoustic Neurinomas According to 3-D Tumor Volume Shrinkage and Quality of Life

Correlation of quality of life and functional outcome measures for cervical spondylotic myelopathy

Contact Info

Product

Resources

About